<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187365</url>
  </required_header>
  <id_info>
    <org_study_id>STU00210382</org_study_id>
    <nct_id>NCT04187365</nct_id>
  </id_info>
  <brief_title>Optimizing the Management of Postpartum Urinary Retention</brief_title>
  <acronym>PUR</acronym>
  <official_title>Optimizing the Management of Postpartum Urinary Retention: Postpartum Urinary Retention (PUR) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study aimed at characterizing the comparing duration of catheterization for treatment of
      postpartum urinary retention (PUR) and characterizing short and long-term pelvic floor
      symptoms in women who have PUR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare clinical outcomes of women with bladder distension
      injuries due to postpartum urinary retention (PUR) who have varying duration of
      catheterization for initial treatment of postpartum urinary retention.

      Hypotheses

        1. Longer duration of therapeutic catheterization will be associated with resolution of
           postpartum voiding dysfunction in women who sustain severe bladder distension injuries
           due to postpartum urinary retention.

           Definition of resolution of postpartum voiding dysfunction:

           A. A post void residual volume of less than half of initial instilled volume on the
           first retrograde voiding trial, AND B. No need for re-treatment for urinary retention
           within 1 week

        2. The incidence of postpartum urinary retention (PUR) will vary by route of delivery, with
           operative vaginal delivery having the highest incidence.

        3. Risk factors for PUR will be related to intrapartum and delivery conditions
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In Arm 2, women with severe postpartum urinary retention will be randomized to 3 or 7 days of foley catheter.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate whether 3 days of indwelling catheterization is inferior to 7 days in resolving postpartum urinary retention.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>GROUP 1 (NonSevere PUR and women without PUR)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 2 (Severe PUR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Duration of Indwelling Catheter</intervention_name>
    <description>Foley catheter</description>
    <arm_group_label>GROUP 2 (Severe PUR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18.

          2. Vaginal or cesarean delivery at term (37 weeks gestational age or later) of live-born
             infants.

          3. English or Spanish speaking and reading.

        Exclusion Criteria:

          1. Adults unable to consent.

          2. Women under the age of 18.

          3. Women who are currently pregnant (All women in the study will have already delivered).

          4. Prisoners or detained individuals.

          5. Women who chronically use a urinary catheter for another medical condition.

          6. Women with a neurological disease with bladder manifestations (examples:
             Cerebrovascular accidents, Multiple sclerosis, Parkinson disease, cerebral palsy).

          7. Women with preeclampsia requiring magnesium treatment for seizure prevention.

          8. Women with prior PUR

          9. Women on anticholinergic medications.

         10. Women who are actively being treated for a UTI.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Collins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylwia Clarke, B.A</last_name>
    <phone>312-695-7748</phone>
    <email>sylwia.clarke@nm.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pooja Sharma, BA/BS</last_name>
    <phone>312-96-7846</phone>
    <email>pooja.sharma@nm.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylwia Clarke, B.A</last_name>
      <phone>312-695-7748</phone>
      <email>sylwiaclarke@nm.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Collins, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alan Peaceman, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oluwateniola Brown, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shweta Hosakoppal</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Sarah Collins</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

